Engerix B 10mcg/0.5ml Vaccine Details

The article was consulted professionally by Specialist Doctor II Huynh Thi Diem Thuy – Vaccine Consultant – Pediatrics – Newborn Department, Share99 Central Park International Health Hub.

The Engerix B 10mcg/0.5ml vaccine is manufactured by Belgian firm Glaxo SmithKline (GSK). Engerix 10mcg/0.5ml is a vaccine against hepatitis B.

Engerix B 10mcg/0.5ml is a vaccine to prevent hepatitis B, manufactured by Belgian firm Glaxo SmithKline (GSK) – one of the leading companies in three main areas: Pharmaceuticals, Vaccines and Healthcare. Engerix B 10mcg/0.5ml vaccine has the registration number QLVX-933-16 issued on February 5, 2016 by the Drug Administration, Ministry of Health.

For Engerix B vaccines with a content of 10mcg/0.5ml canned according to the following types: Box of 1 vial of 0.5ml vaccine; Box of 10 0.5ml vaccine vials; Box of 25 0.5ml vaccine vials.

• A mixture for injection
• The mixture is white, slightly opaque

During storage, fine white precipitations with colorless floating air can be observed.

Engerix B 10mcg/ 0.5ml hepatitis B prevention for all at-risk subjects exposed to hepatitis B virus at all ages: infants, young children, adolescents, adults up to 19 years old are at high risk…

In areas with low rates of hepatitis B, vaccination is recommended specifically for those at high risk of infection

The World Health Organization, the American Immunization Advisory Council (ACIP) and the American Pediatric Association recommend that infant and adolescent vaccinations be the optimal strategy for controlling hepatitis B in every country.

The target group was noted to be at high risk of infection:

• Medical staff
• Patients regularly receive blood products
• Staff and residents in nursing homes or emergency camps
• People at high risk due to sexual activity
• Drug injecters
• Travelers to areas with high circulating hepatitis B
• Babies born to HBV-carrying mothers
• People from regions with highly circulating hepatitis B
• Patients with sickle cell anemia
• Patients receiving organ transplants
• Close family contact with one of the above groups or with patients with acute or chronic HBV infection
• Subjects with chronic liver disease or at risk of developing chronic liver disease (such as hepatitis C virus carryers,alcoholics)
• Others: police officers, firefighters, military personnel and those potentially exposed to HBV due to their work or way of life.

4.1 Vaccination schedule:

The Engerix B 10mcg/0.5ml vaccine is used to immunization babies up to the age of 19. The Engerix B 20mcg/1ml vaccine is used to vaccinate people aged 20 and over.

The basic vaccination schedule has 2 options for the injection regimen:

Way 1: Antibody price is fast

• Nose 1: Babies born should be injected in the first month after birth or performed in the first visit to the injection
• Nose 2: After 1 injection for 01 month
• Nose 3: After 2 injections for 01 month
• Nose 4: Repeat after 3 injections for 01 year.

Way 2: Antibody price is high after 3 injections

• Nose 1: Babies born should be injected in the first month after birth or performed in the first visit to the injection
• Nose 2: After 1 injection for 01 month
• Nose 3: After 2 injections for 06 months

Repeat injection 4 after 3 injections for 05 years.

Method 3 – Fast vaccination schedule: For those who need quick protection (needle piercing suspected hepatitis B virus infection; or preparing to enter areas with high incidence of hepatitis B…)

• Nose 1: Perform the first time to the injection
• Nose 2: After 1 injection for 07 days
• Nose 3: After 2 injections are 21 days.

4.2 Line of use

The Engerix B vaccine is intramuscularly intramuscularly given (delta muscle area) for adults and older children, injected into the frontal area of the thigh with babies, infants, young children. Exceptions, for patients with bleeding disorders or tingle cells may be injected subcutaneously.

Do not inject Engerix B enters the buttocks or in the skin due to possible poor immune response.

• Engerix-B should not be given to subjects who are known to be hypersensitive to one of the components of the vaccine or who present with hypersensitivity to the vaccine at the previous injection.
• HIV infection is not considered contrainctrained for hepatitis B vaccination.

• Engerix B injections should be postponed for high-end fever subjects. However, vaccination is not contrained in cases where mild infection is present.
• Due to the long incubation period of hepatitis B, it is possible that the body already has the virus without knowing and going to get vaccinated, the vaccine will not be able to prevent viral infection.
• The vaccine has no preventive effect on hepatitis A, C, and hepatitis E infections.
• Patients with renal impairment include patients with hemodialysis, HIV infection, and those with weakened immune systems who may not achieve adequate HBs antibody effects following basic vaccination regimens. Therefore additional doses should be given to these patients.
• Like all vaccines, medical facilities must always be prepared to prevent antisymic shock.
• When injecting premature babies (under 28 weeks of age) especially those with an incomplete history of respiratory system, the risk of potential apnea should be considered and the respiratory system should be monitored within 48-72 hours after injection. Due to the high benefits of vaccination against this group, vaccination should not be cancelled or delayed.
• Do not inject into the buttocks or in the skin due to a low immune response.
• Intravenously should not be given under any case.

common:

• At the injection site: transient pain, arye, skin hardening bottles.

Rare:

• Whole body: fatigue, fever, discomfort, symptoms such as flu.
• Central and peripheral nervous system: dizziness, headache, heteropathic.
• Digestive system: nausea, vomiting, diarrhea, abdominal pain.
• Hepatic bile system: results of altered liver function tests.
• Myaloid system: joint pain, muscle pain.
• Skin and sub-parts of the skin: rash, itching, urticaria.

Very rare:

• Whole body: antisymic reaction.
• Cardiovascular: fainting, hypotension.
• Central and peripheral nervous system: paralysis, neurological diseases, neurological inflammation (including Guillain-Barré syndrome, octis and polynural fibrosis), encephalitis, encephaositis, meningitis.
• Respiratory system: symptoms of bronchospasm type.
• Extracardiac vascular system: inflammation of the vessels.
• Leukocylthatic system and end tissue mesh: lymphadenopathy.

Shelf Life: 36 months from the date of manufacture The shelf life of the Vaccine is in written on the label and case.

Special caution when preserving:

The Engerix B vaccine is preserved at temperatures between +2 degrees Celsius and +8 degrees Celsius and does not freeze, avoiding light.

Source: Information in the article is referenced from EngerixTM-B Product Prescribing Information